A Multistate Outbreak of


Journal

Pediatrics
ISSN: 1098-4275
Titre abrégé: Pediatrics
Pays: United States
ID NLM: 0376422

Informations de publication

Date de publication:
10 2019
Historique:
accepted: 02 07 2019
pubmed: 15 9 2019
medline: 25 1 2020
entrez: 15 9 2019
Statut: ppublish

Résumé

In 2017, we conducted a multistate investigation to determine the source of an outbreak of Shiga toxin-producing We defined a case as infection with an outbreak strain of STEC O157:H7 with illness onset between January 1, 2017, and April 30, 2017. Case patients were interviewed to identify common exposures. Traceback and facility investigations were conducted; food samples were tested for STEC. We identified 32 cases from 12 states. Twenty-six (81%) cases occurred in children <18 years old; 8 children developed hemolytic uremic syndrome. Twenty-five (78%) case patients ate the same brand of soy nut butter or attended facilities that served it. We identified 3 illness subclusters, including a child care center where person-to-person transmission may have occurred. Testing isolated an outbreak strain from 11 soy nut butter samples. Investigations identified violations of good manufacturing practices at the soy nut butter manufacturing facility with opportunities for product contamination, although the specific route of contamination was undetermined. This investigation identified soy nut butter as the source of a multistate outbreak of STEC infections affecting mainly children. The ensuing recall of all soy nut butter products the facility manufactured, totaling >1.2 million lb, likely prevented additional illnesses. Prompt diagnosis of STEC infections and appropriate specimen collection aids in outbreak detection. Child care providers should follow appropriate hygiene practices to prevent secondary spread of enteric illness in child care settings. Firms should manufacture ready-to-eat foods in a manner that minimizes the risk of contamination.

Sections du résumé

BACKGROUND
In 2017, we conducted a multistate investigation to determine the source of an outbreak of Shiga toxin-producing
METHODS
We defined a case as infection with an outbreak strain of STEC O157:H7 with illness onset between January 1, 2017, and April 30, 2017. Case patients were interviewed to identify common exposures. Traceback and facility investigations were conducted; food samples were tested for STEC.
RESULTS
We identified 32 cases from 12 states. Twenty-six (81%) cases occurred in children <18 years old; 8 children developed hemolytic uremic syndrome. Twenty-five (78%) case patients ate the same brand of soy nut butter or attended facilities that served it. We identified 3 illness subclusters, including a child care center where person-to-person transmission may have occurred. Testing isolated an outbreak strain from 11 soy nut butter samples. Investigations identified violations of good manufacturing practices at the soy nut butter manufacturing facility with opportunities for product contamination, although the specific route of contamination was undetermined.
CONCLUSIONS
This investigation identified soy nut butter as the source of a multistate outbreak of STEC infections affecting mainly children. The ensuing recall of all soy nut butter products the facility manufactured, totaling >1.2 million lb, likely prevented additional illnesses. Prompt diagnosis of STEC infections and appropriate specimen collection aids in outbreak detection. Child care providers should follow appropriate hygiene practices to prevent secondary spread of enteric illness in child care settings. Firms should manufacture ready-to-eat foods in a manner that minimizes the risk of contamination.

Identifiants

pubmed: 31519792
pii: peds.2018-3978
doi: 10.1542/peds.2018-3978
pmc: PMC6774848
mid: NIHMS1047994
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Intramural CDC HHS
ID : CC999999
Pays : United States

Informations de copyright

Copyright © 2019 by the American Academy of Pediatrics.

Déclaration de conflit d'intérêts

POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential conflicts of interest to disclose.

Références

Epidemiol Infect. 2018 Oct 08;147:e20
pubmed: 30293540
Emerg Infect Dis. 2011 Jan;17(1):16-22
pubmed: 21192849
Clin Infect Dis. 2017 Nov 29;65(12):e45-e80
pubmed: 29053792
EMBO Rep. 2016 Nov;17(11):1499-1505
pubmed: 27644260
N Engl J Med. 1995 Aug 10;333(6):364-8
pubmed: 7609755
MMWR Morb Mortal Wkly Rep. 2017 Jan 27;66(3):88-89
pubmed: 28125572
Clin Microbiol Rev. 1998 Jul;11(3):450-79
pubmed: 9665978
J Food Sci Technol. 2015 Jul;52(7):3965-76
pubmed: 26139864
Epidemiol Infect. 1999 Apr;122(2):185-92
pubmed: 10355781
Emerg Infect Dis. 2005 Apr;11(4):603-9
pubmed: 15829201
Clin Infect Dis. 2009 Nov 15;49(10):1480-5
pubmed: 19827953
MMWR Morb Mortal Wkly Rep. 2016 Apr 15;65(14):368-71
pubmed: 27077946
J Allergy Clin Immunol. 2017 Aug;140(2):391-392
pubmed: 28454741
Epidemiol Infect. 2017 Jun;145(8):1535-1544
pubmed: 28318456
Front Microbiol. 2017 Mar 13;8:375
pubmed: 28348549
Clin Infect Dis. 2018 Aug 31;67(6):890-896
pubmed: 29522200
J Clin Microbiol. 2016 Dec 28;55(1):10-19
pubmed: 27795338
Clin Infect Dis. 2012 Feb 15;54(4):511-8
pubmed: 22157169
Mol Biol Evol. 2016 Jul;33(7):1870-4
pubmed: 27004904
Epidemiol Rev. 1991;13:60-98
pubmed: 1765120
Semin Hematol. 1987 Jul;24(3):148-60
pubmed: 3310240
Emerg Infect Dis. 2015 Aug;21(8):1293-1301
pubmed: 26197993

Auteurs

Rashida Hassan (R)

Centers for Disease Control and Prevention, Atlanta, Georgia; rhassan1@cdc.gov.
Caitta, Inc, Herndon, Virginia.

Sharon Seelman (S)

US Food and Drug Administration, College Park, Maryland.

Vi Peralta (V)

California Department of Public Health, Sacramento, California.
California Department of Public Health, Richmond, California.

Hillary Booth (H)

Oregon Health Authority, Portland, Oregon.

Mackenzie Tewell (M)

Arizona Department of Health Services, Phoenix, Arizona.

Beth Melius (B)

Washington State Department of Health, Shoreline, Washington.

Brooke Whitney (B)

US Food and Drug Administration, College Park, Maryland.

Rosemary Sexton (R)

US Food and Drug Administration, College Park, Maryland.

Asha Dwarka (A)

US Food and Drug Administration, College Park, Maryland.

Duc Vugia (D)

California Department of Public Health, Sacramento, California.
California Department of Public Health, Richmond, California.

Jeff Vidanes (J)

California Department of Public Health, Sacramento, California.
California Department of Public Health, Richmond, California.

David Kiang (D)

California Department of Public Health, Sacramento, California.
California Department of Public Health, Richmond, California.

Elysia Gonzales (E)

Public Health-Seattle and King County, Seattle, Washington.

Natasha Dowell (N)

Centers for Disease Control and Prevention, Atlanta, Georgia.
Eagle Medical Services, Huntsville, Alabama.

Samantha M Olson (SM)

Centers for Disease Control and Prevention, Atlanta, Georgia.
GS Corporation, San Antonio, Texas; and.

Lori M Gladney (LM)

Centers for Disease Control and Prevention, Atlanta, Georgia.

Michael A Jhung (MA)

Centers for Disease Control and Prevention, Atlanta, Georgia.

Karen P Neil (KP)

Centers for Disease Control and Prevention, Atlanta, Georgia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH